Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7006 to 7020 of 7675 results

  1. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

    Discontinued [GID-TA10297]

  2. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued [GID-TA10338]

  3. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development [GID-HST10037] Expected publication date: TBC

  4. Lasmiditan for treating acute migraine [ID3759]

    Discontinued [GID-TA10807]

  5. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    In development [GID-TA10929] Expected publication date: TBC

  6. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued [GID-TA10633]

  7. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued [GID-TA10668]

  8. Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

    Discontinued [GID-TA10737]

  9. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    In development [GID-TA11204] Expected publication date: TBC

  10. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued [GID-TA10527]

  11. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

  12. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    In development [GID-TA10958] Expected publication date: TBC